Literature DB >> 22643706

T-cell receptor diversity prevents T-cell lymphoma development.

S Newrzela1, N Al-Ghaili, T Heinrich, M Petkova, S Hartmann, B Rengstl, A Kumar, H-M Jäck, S Gerdes, I Roeder, M-L Hansmann, D von Laer.   

Abstract

Mature T-cell lymphomas (MTCLs) have an extremely poor prognosis and are much less frequent than immature T-cell leukemias. This suggests that malignant outgrowth of mature T lymphocytes is well controlled. Indeed, in a previous study we found that mature T cells are resistant to transformation with known T-cell oncogenes. Here, however, we observed that T-cell receptor (TCR) mono-/oligoclonal mature T cells from TCR transgenic (tg) mice (OT-I, P14) expressing the oncogenes NPM/ALK or ΔTrkA readily developed MTCLs in T-cell-deficient recipients. Analysis of cell surface markers largely ruled out that TCR tg lymphomas were derived from T-cell precursors. Furthermore, cotransplanted non-modified TCR polyclonal T cells suppressed malignant outgrowth of oncogene expressing TCR tg T lymphocytes. A dominant role of an anti-leukemic immune response or Tregs in the control of MTCLs seems unlikely as naïve T cells derived from oncogene expressing stem cells, which should be tolerant to leukemic antigens, as well as purified CD4 and CD8 were resistant to transformation. However, our results are in line with a model in which homeostatic mechanisms that stabilize the diversity of the normal T-cell repertoire, for example, clonal competition, also control the outgrowth of potentially malignant T-cell clones. This study introduces a new innate mechanism of lymphoma control.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22643706     DOI: 10.1038/leu.2012.142

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  24 in total

Review 1.  T cell engineering as therapy for cancer and HIV: our synthetic future.

Authors:  Carl H June; Bruce L Levine
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

2.  The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Authors:  Qian Zhang; Fang Wei; Hong Yi Wang; Xiaobin Liu; Darshan Roy; Qun-Bin Xiong; Shuguang Jiang; Andrew Medvec; Gwenn Danet-Desnoyers; Christopher Watt; Ewa Tomczak; Michael Kalos; James L Riley; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2013-12       Impact factor: 4.307

3.  Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.

Authors:  Pablo Vieyra-Garcia; Regina Fink-Puches; Stefanie Porkert; Roland Lang; Sophie Pöchlauer; Gudrun Ratzinger; Adrian Tanew; Sylvia Selhofer; Sator Paul-Gunther; Angelika Hofer; Alexandra Gruber-Wackernagel; Franz Legat; Vijaykumar Patra; Franz Quehenberger; Lorenzo Cerroni; Rachael Clark; Peter Wolf
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

Review 4.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

5.  Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development.

Authors:  Darío Lirussi; Thomas Ebensen; Kai Schulze; Elena Reinhard; Stephanie Trittel; Peggy Riese; Blair Prochnow; Carlos A Guzmán
Journal:  J Vis Exp       Date:  2018-06-19       Impact factor: 1.355

6.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

8.  Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

Authors:  Tim Heinrich; Benjamin Rengstl; Alexander Muik; Mina Petkova; Frederike Schmid; Robin Wistinghausen; Kathrin Warner; Giuliano Crispatzu; Martin-Leo Hansmann; Marco Herling; Dorothee von Laer; Sebastian Newrzela
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

Review 9.  T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Authors:  Kathrin Warner; Nicole Weit; Giuliano Crispatzu; Joan Admirand; Dan Jones; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

10.  NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice.

Authors:  Sigrid Dubois; Lionel Feigenbaum; Thomas A Waldmann; Jürgen R Müller
Journal:  Cell Immunol       Date:  2020-02-27       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.